person · Reporting owner

Robinson James A. Jr.

Disclosed activity across 6 companies

Tapewire entity: 18718
SEC CIK: 0001734295

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	President & COO,Alkermes, Inc.	April 04, 2019	April 05, 2019
Eledon Pharmaceuticals, Inc.ELDN · Entity 6160	Director	January 10, 2026	January 16, 2026
UroGen Pharma Ltd.URGN · Entity 4466	Director	August 26, 2026	August 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date April 04, 2019 · Filed April 05, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	4,412	Ending reported balance After 2019-04-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-04-04 · Exercise / conversion · Acquired 6,250 · Balance 6,250 Row 2 · 2019-04-04 · Tax withholding · Disposed 1,838 · Balance 4,412
Restricted Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	18,750	Reported balance After 2019-04-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-04-04 · Exercise / conversion · Disposed 6,250 · Balance 18,750 F1: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019.

Filing footnotes · ownership attribution and instrument terms

F1: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019.

Eledon Pharmaceuticals, Inc.

Report date January 10, 2026 · Filed January 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,430	Reported balance After 2026-01-10 transaction · row 1 1 source row Row 1 · 2026-01-10 · Exercise / conversion · Acquired 3,430 · Balance 3,430 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-01-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-10 · Exercise / conversion · Disposed 3,430 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.

UroGen Pharma Ltd.

Report date August 26, 2026 · Filed August 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
ordinary sharesSEC Table I · non-derivative	Direct	8,000	Reported balance After 2026-08-26 transaction · row 1 1 source row Row 1 · 2026-08-26 · Exercise / conversion · Acquired 2,000 · Balance 8,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-08-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-26 · Exercise / conversion · Disposed 2,000 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

APPLIED GENETIC TECHNOLOGIES CORP

Report date November 30, 2022 · Filed December 01, 2022

Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30	Direct	0	Reported balance After 2022-11-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-11-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Neos Therapeutics, Inc.

Report date March 19, 2021 · Filed March 19, 2021

Section 16 reporting ended · disclosed 2021-03-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-03-19 transaction · row 1 1 source row Row 1 · 2021-03-19 · Disposition to issuer · Disposed 23,453 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03	Direct	Reported balance After 2021-03-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44	Direct	Reported balance After 2021-03-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-19 · Disposition to issuer · Disposed 46,907 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement).

F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.

F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.

Urovant Sciences Ltd.

Report date March 29, 2021 · Filed March 31, 2021

Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 1 1 source row Row 1 · 2021-03-29 · Disposition to issuer · Disposed 8,385 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.41 · Expires 2029-03-01	Direct	Reported balance After 2021-03-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-29 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09	Direct	Reported balance After 2021-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-29 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Appreciation Right (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2030-03-22	Direct	Reported balance After 2021-03-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-29 · Disposition to issuer · Disposed 845,732 · Balance 0 F3: Upon consummation of the Merger, each right to receive an appreciation on Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had a strike price per Common Share that is less than $16.25 was canceled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such appreciation right that is equal to the difference between $16.25 and the strike price per Common Share of such appreciation right, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F3: Upon consummation of the Merger, each right to receive an appreciation on Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had a strike price per Common Share that is less than $16.25 was canceled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such appreciation right that is equal to the difference between $16.25 and the strike price per Common Share of such appreciation right, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 10, 2035 Filed Jan 13, 2025 22:30 UTC	Eledon Pharmaceuticals, Inc. ELDN · Entity 6160	GrantStock Option (right to buy) · Derivative	30,870	$0.00 Strike: $4.04	$0.00	Disclosure SEC source: 0000950170-25-004920 · ownership.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,870 Underlying: Common Stock · 30,870 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026. Read SEC document
August 26, 2026 Filed Aug 28, 2026 16:01 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Unit · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-029175 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
August 26, 2026 Filed Aug 28, 2026 16:01 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionordinary shares	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-029175 · rdgdoc.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
June 22, 2026 Filed Jun 24, 2026 14:02 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-021517 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
June 22, 2026 Filed Jun 24, 2026 14:02 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $34.99	$0.00	Disclosure SEC source: 0001437749-26-021517 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
May 26, 2026 Filed May 27, 2026 12:04 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Unit · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-018442 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
May 26, 2026 Filed May 27, 2026 12:04 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionordinary shares	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-018442 · rdgdoc.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
January 10, 2026 Filed Jan 16, 2026 22:00 UTC	Eledon Pharmaceuticals, Inc. ELDN · Entity 6160	Exercise / conversionRestricted Stock Units · Derivative	3,430	$0.00	$0.00	Disclosure SEC source: 0001193125-26-015484 · ownership.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document
January 10, 2026 Filed Jan 16, 2026 22:00 UTC	Eledon Pharmaceuticals, Inc. ELDN · Entity 6160	Exercise / conversionCommon Stock	3,430	$0.00	$0.00	Disclosure SEC source: 0001193125-26-015484 · ownership.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:47 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Unit · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001437749-25-036559 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:47 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionordinary shares	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-036559 · rdgdoc.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
August 26, 2025 Filed Aug 27, 2025 20:39 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001437749-25-027882 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
August 26, 2025 Filed Aug 27, 2025 20:39 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $19.50	$0.00	Disclosure SEC source: 0001437749-25-027882 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2035-08-26 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
February 26, 2025 Filed Feb 27, 2026 21:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Unit · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-006124 · rdgdoc.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
February 26, 2025 Filed Feb 27, 2026 21:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionordinary shares	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-006124 · rdgdoc.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
January 10, 2025 Filed Jan 13, 2025 22:30 UTC	Eledon Pharmaceuticals, Inc. ELDN · Entity 6160	GrantRestricted Stock Units · Derivative	3,430	$0.00	$0.00	Disclosure SEC source: 0000950170-25-004920 · ownership.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the total restricted stock units will vest on January 10, 2026. F3 · derivative.expiration_date: 100% of the total restricted stock units will vest on January 10, 2026. Read SEC document
August 06, 2024 Filed Aug 8, 2024 13:08 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $15.16	$0.00	Disclosure SEC source: 0001437749-24-025293 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
October 02, 2023 Filed Oct 3, 2023 20:19 UTC	Eledon Pharmaceuticals, Inc. ELDN · Entity 6160	GrantStock Option (Right to Buy) · Derivative	150,437	$1.55 Strike: $1.55	$233,177.35	Disclosure SEC source: 0001209191-23-051460 · doc4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-10-02 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on October 2, 2024 and with respect to 75,218 shares on October 2, 2025. Read SEC document
September 07, 2023 Filed Sep 8, 2023 19:41 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $16.85	$0.00	Disclosure SEC source: 0001437749-23-025481 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2033-09-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
July 25, 2023 Filed Jul 27, 2023 20:30 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $8.90	$0.00	Disclosure SEC source: 0001437749-23-020905 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-07-25 F1 · derivative.exercise_date: The shares underlying the stock option vest in equal quarterly installments over 12 months Read SEC document
July 25, 2023 Filed Jul 28, 2023 22:05 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $8.84	$0.00	Disclosure SEC source: 0001437749-23-021072 · rdgdoc.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2033-07-25 F1 · derivative.exercise_date: The shares underlying the stock option vest in equal quarterly installments over 12 months Read SEC document
November 30, 2022 Filed Dec 1, 2022 09:23 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $2.17	Not disclosed	Disclosure SEC source: 0001062993-22-023030 · form4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2031-11-30 F1 · price: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. F1 · derivative.exercise_date: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. Read SEC document
November 30, 2021 Filed Dec 2, 2021 19:53 UTC	APPLIED GENETIC TECHNOLOGIES CORP AGTC · Entity 121949	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $2.17	$0.00	Disclosure SEC source: 0001062993-21-012070 · form4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-11-30 F1 · derivative.exercise_date: Option becomes exercisable for one third of the underlying shares on the first anniversary of the grant date, and thereafter becomes exercisable for the remaining underlying shares, in equal monthly installments over two years, resulting in the option being exercisable for 100% of the underlying shares on the third anniversary of the grant date. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Appreciation Right (Right to Buy) · Derivative	845,732	$0.00 Strike: $9.16	$0.00	Disclosure SEC source: 0000899243-21-014110 · doc4.xml · derivative · entry 4 Robinson James A. Jr. · CIK 0001734295 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 845,732 shares Expires 2030-03-22 F3 · derivative.exercise_date: Upon consummation of the Merger, each right to receive an appreciation on Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had a strike price per Common Share that is less than $16.25 was canceled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such appreciation right that is equal to the difference between $16.25 and the strike price per Common Share of such appreciation right, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0000899243-21-014110 · doc4.xml · derivative · entry 3 Robinson James A. Jr. · CIK 0001734295 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F2 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $12.41	$0.00	Disclosure SEC source: 0000899243-21-014110 · doc4.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2029-03-01 F2 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 16:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerCommon Shares	8,385	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-014110 · doc4.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:36 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerStock Option (Right to Buy) · Derivative	46,907	$0.00 Strike: $1.44	$0.00	Disclosure SEC source: 0001104659-21-039230 · tm219870-13_4seq1.xml · derivative · entry 3 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,907 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:36 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0001104659-21-039230 · tm219870-13_4seq1.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document
March 19, 2021 Filed Mar 19, 2021 17:36 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	Disposition to issuerCommon Stock	23,453	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-039230 · tm219870-13_4seq1.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3 · shares: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). Read SEC document
January 10, 2021 Filed Jan 13, 2021 00:02 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Tax withholdingCommon Shares	4,095	$16.11	$65,970.45	Disclosure SEC source: 0001209191-21-003314 · doc4.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director · PEO; CEO/Urovant Sciences, Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,385 F1 · shares: Represents shares of common stock withheld by the Issuer to pay tax withholding obligations of the Reporting Person upon the vesting of restricted stock units previously granted to the Reporting Person. Read SEC document
June 10, 2020 Filed Jun 11, 2020 20:23 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantCommon Stock	23,453	$0.00	$0.00	Disclosure SEC source: 0001104659-20-072549 · a4.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,453 F1 · security: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest on the one-year anniversary of June 10, 2020. Read SEC document
March 23, 2020 Filed Mar 25, 2020 21:00 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Appreciation Right (Right to Buy) · Derivative	845,732	$0.00 Strike: $9.16	$0.00	Disclosure SEC source: 0000899243-20-009409 · doc4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director · PEO;CEO/Urovant Sciences, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,732 Underlying: Common Shares · 845,732 shares Expires 2030-03-22 F1 · derivative.exercise_date: 25% of the stock appreciation rights ("SARs") shall vest and become exercisable on March 23, 2021; the remaining SARs vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. F2 · derivative.underlying: The SARs may be settled in cash or in the Issuer's common shares. Read SEC document
January 10, 2020 Filed Jan 14, 2020 21:09 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantCommon Shares	12,480	$0.00	$0.00	Disclosure SEC source: 0001209191-20-003287 · doc4.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,480 F1 · shares: The Restricted Stock Units shall vest on January 10, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
July 09, 2019 Filed Jul 11, 2019 17:16 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0001209191-19-041792 · doc4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:33 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantStock Option (Right to Buy) · Derivative	46,907	$0.00 Strike: $1.44	$0.00	Disclosure SEC source: 0001104659-19-035983 · a4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,907 Underlying: Common Stock · 46,907 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which began on June 13, 2019. Read SEC document
April 04, 2019 Filed Apr 5, 2019 21:10 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	6,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-014943 · form4.xml · derivative · entry 3 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Ordinary Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019. Read SEC document
April 04, 2019 Filed Apr 5, 2019 21:10 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,838	$35.89	$65,965.82	Disclosure SEC source: 0001127602-19-014943 · form4.xml · nonDerivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412 Read SEC document
April 04, 2019 Filed Apr 5, 2019 21:10 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,250	$0.00	$0.00	Disclosure SEC source: 0001127602-19-014943 · form4.xml · nonDerivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2019 Filed Mar 6, 2019 01:44 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $12.41	$0.00	Disclosure SEC source: 0001209191-19-017192 · doc4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on March 1, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document
February 21, 2019 Filed Feb 25, 2019 22:34 UTC	Alkermes plc. ALKS · Entity 2392	GrantEmployee Stock Option (Right to Buy) · Derivative	157,000	$0.00 Strike: $32.57	$0.00	Disclosure SEC source: 0001127602-19-008127 · form4.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,000 Underlying: Ordinary Shares · 157,000 shares Expires 2029-02-21 F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020. Read SEC document
February 21, 2019 Filed Feb 25, 2019 22:34 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	40,400	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-008127 · form4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,400 Underlying: Ordinary Shares · 40,400 shares Expires not disclosed F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020. Read SEC document
January 29, 2019 Filed Jan 30, 2019 17:37 UTC	Neos Therapeutics, Inc. NEOS · Entity 141061	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0001104659-19-004506 · a4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-01-29 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a two-year period which began on January 29, 2019. Read SEC document
April 04, 2018 Filed Jul 3, 2018 21:06 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	25,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-022684 · form4.xml · derivative · entry 2 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires not disclosed F1 · date: Late filing due to administrative error. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments commencing on 4/4/2019. Read SEC document
April 04, 2018 Filed Jul 3, 2018 21:06 UTC	Alkermes plc. ALKS · Entity 2392	GrantEmployee Stock Option (Right to Buy) · Derivative	140,000	$44.16 Strike: $44.16	$6,182,400.00	Disclosure SEC source: 0001127602-18-022684 · form4.xml · derivative · entry 1 Robinson James A. Jr. · CIK 0001734295 · President & COO,Alkermes, Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Ordinary Shares · 140,000 shares Expires 2028-04-04 F1 · date: Late filing due to administrative error. F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 4/4/2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.